• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Proc Natl Acad Sci U S A . In silico dynamics of COVID-19 phenotypes for optimizing clinical management

tetano

Editor, Senior Moderator
Proc Natl Acad Sci U S A


. 2021 Jan 19;118(3):e2021642118.
doi: 10.1073/pnas.2021642118.
In silico dynamics of COVID-19 phenotypes for optimizing clinical management


Chrysovalantis Voutouri[SUP] 1 [/SUP], Mohammad Reza Nikmaneshi[SUP] 2 3 [/SUP], C Corey Hardin[SUP] 4 [/SUP], Ankit B Patel[SUP] 5 [/SUP], Ashish Verma[SUP] 5 [/SUP], Melin J Khandekar[SUP] 6 [/SUP], Sayon Dutta[SUP] 7 [/SUP], Triantafyllos Stylianopoulos[SUP] 8 [/SUP], Lance L Munn[SUP] 9 [/SUP], Rakesh K Jain[SUP] 9 [/SUP]



Affiliations

Abstract

Understanding the underlying mechanisms of COVID-19 progression and the impact of various pharmaceutical interventions is crucial for the clinical management of the disease. We developed a comprehensive mathematical framework based on the known mechanisms of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, incorporating the renin-angiotensin system and ACE2, which the virus exploits for cellular entry, key elements of the innate and adaptive immune responses, the role of inflammatory cytokines, and the coagulation cascade for thrombus formation. The model predicts the evolution of viral load, immune cells, cytokines, thrombosis, and oxygen saturation based on patient baseline condition and the presence of comorbidities. Model predictions were validated with clinical data from healthy people and COVID-19 patients, and the results were used to gain insight into identified risk factors of disease progression including older age; comorbidities such as obesity, diabetes, and hypertension; and dysregulated immune response. We then simulated treatment with various drug classes to identify optimal therapeutic protocols. We found that the outcome of any treatment depends on the sustained response rate of activated CD8[SUP]+[/SUP] T cells and sufficient control of the innate immune response. Furthermore, the best treatment-or combination of treatments-depends on the preinfection health status of the patient. Our mathematical framework provides important insight into SARS-CoV-2 pathogenesis and could be used as the basis for personalized, optimal management of COVID-19.

Keywords: COVID-19; SARS-CoV-2; mathematical model; simulation.
 
Back
Top Bottom